Edition:
United Kingdom

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

8.73USD
3:46pm GMT
Change (% chg)

$0.12 (+1.39%)
Prev Close
$8.61
Open
$8.55
Day's High
$8.73
Day's Low
$8.55
Volume
1,656
Avg. Vol
14,255
52-wk High
$11.34
52-wk Low
$5.82

Chart for

About

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $147.73
Shares Outstanding(Mil.): 13.32
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Oramed receives approval for clinical study to treat NASH

* Oramed receives regulatory approval to conduct clinical study for treatment of NASH with its oral insulin capsule

14 Nov 2017

BRIEF-Oramed pharmaceuticals ‍concludes its meeting with U.S. FDA regarding its oral insulin formulation​

* ‍Concluded its meeting with U.S. FDA regarding ORMD-0801, company's novel oral insulin formulation​

05 Sep 2017

BRIEF-Oramed Pharmaceuticals Inc's CFO Yifat Zommer resigned from her positions with co per personal reasons

* Oramed Pharmaceuticals Inc - on July 18, yifat zommer, cfo of co resigned from her positions with co per personal reasons, effective August 1, 2017

21 Jul 2017

BRIEF-Oramed announces dual-listing on Tel Aviv stock exchange

* Oramed Pharmaceuticals Inc - ‍Based on current market capitalization of company, it is expected that Oramed will be included in TA SME-60 index​

05 Jul 2017

BRIEF-Oramed granted Japanese patent for combination insulin and glp-1 analog capsule

* Oramed granted Japanese patent for combination insulin and glp-1 analog capsule

27 Jun 2017

Earnings vs. Estimates